TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00307684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: double blind placebo
Description: matching placebo tablets once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: double blind PR OROS methylphenidate
Description: 18, 36, 54,72 or 90 mg/day once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open label PR OROS methylphenidate
Description: Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
Study: NCT04023500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview vs. prevailing education
Description: In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview vs. prevailing education
Description: In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care.
Study: NCT02828540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT047 High-dose group
Description: HT047 2250mg, three times a day dosing schedule, 3 tablets per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT047 Low-dose group
Description: HT047 1500mg, three times a day dosing schedule, 3 tablets per dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo having the same appearance as HT047 Tab. 250mg
Study: NCT00951002

Intervention type: PROCEDURE
Intervention: acellular dermal matrix plug
Description: anal fistula treated with human acellular dermal matrix plug
Study: NCT02816177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT04488627

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional transthoracic echocardiographic examination at the intensive care unit.
Description: Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
Study: NCT05243238

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement flavonoids
Description: patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement flavonoids
Description: patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement flavonoids
Description: patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention
Study: NCT05861700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L
Description: A change Dbic in a middle of hemodialysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L
Description: A change Dbic in a middle of hemodialysis
Study: NCT02587988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for HCP1302)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for HGP0904)
Study: NCT04033666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal cannula
Description: The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV Noninvasive Ventilation
Description: The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
Study: NCT03292432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TERA Intervention (TERA)
Description: A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
Study: NCT02875886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: Combined with hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Combined with amiloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium diet
Study: NCT04461093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure wristband and Palanosetron
Description: Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure wristband and Palanosetron
Description: Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction.
Study: NCT05526079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchfuf waiting
Description: Careful review of patient response with the hope of avoiding radical surgery.
Study: NCT02557529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: 12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Description: Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet diary
Description: Weekly diet diary during the 12-weeks intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet diary
Description: Weekly diet diary during the 12-weeks intervention
Study: NCT03898037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention
Description: weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention
Description: weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin intervention
Description: metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin intervention
Description: metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
Study: NCT02704793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral 1 Hz Cerebellar rTMS
Description: 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (electrical stimulation)
Description: 900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
Study: NCT03025685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRUST technique
Description: A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchoring Technique
Description: A standard endovascular technique of coronary wire support improvement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: A standard endovascular procedure of percutaneous coronary intervention with coronary stenting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Description: A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
Study: NCT02876159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2016-2017 Influenza Vaccine
Description: Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2016-2017 Influenza Vaccine
Description: Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
Study: NCT03526276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP paste
Description: Children will brush their teeth with CPP-ACP paste twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Children will brush their teeth with fluoridated toothpaste twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Both (Fluoride and CPP-ACP)
Description: Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
Study: NCT02553967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: Functional MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: Functional MRI
Study: NCT04686201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Mobile Application
Description: incorporating mobile application usage in managing diabetes mellitus patient in health clinics
Study: NCT04539535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day
Description: Different surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day
Description: Different surface
Study: NCT02235831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A MF contact lenses (DACP MF)
Description: Multifocal contact lenses in Low, Medium, High Add

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A MF contact lenses (DACP MF)
Description: Multifocal contact lenses in Low, Medium, High Add

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A MF contact lenses (DACP MF)
Description: Multifocal contact lenses in Low, Medium, High Add

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A single vision contact lenses (DACP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A single vision contact lenses (DACP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A single vision contact lenses (DACP)
Study: NCT02934256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
Study: NCT01283204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: \<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FL/Tax
Description: \<Every q 3 weeks\>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FL/Doc
Description: \<Every q 3 weeks\>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: \<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
Study: NCT00625261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention HPLI
Description: The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
Study: NCT01739816

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication review
Description: Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication review
Description: Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
Study: NCT00944073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
Study: NCT02001298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroprusside
Study: NCT03629379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
Study: NCT04587752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Weight Bullying
Description: Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
Study: NCT05271370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 350
Description: Pro140 SC injection 350 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 525
Description: 525 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 700
Description: 700 mg
Study: NCT03699553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain
Description: 8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Reporting Control Group
Description: Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
Study: NCT04538001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon implantation
Description: Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
Study: NCT02234648

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 60mL tart Montmorency cherry juice
Description: One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
Study: NCT04490382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 32 channel external stimulator
Description: Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
Study: NCT03535597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quikclot Radial (QC) Pad
Description: The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quikclot Radial (QC) Pad
Description: The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quikclot Radial (QC) Pad
Description: The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.